Fibrous Septa Quantitative assessment of liver fibrosis HistoIndex Credits1 25 May 2020

HistoIndex's AI-based Digital Pathology Platform: A Validate...

Date: 25 May 2020

Singapore medtech company HistoIndex's AI-based stain-free digital pathology platform has long been established as a suitable tool for global clinical guidelines that outline the assessment, prevention and treatment of Chronic Hepatitis B (CHB) infections.

In the latest edition of China's Guidelines for the Prevention and Treatment of Chronic Hepatitis B, the digital pathology platform was recommended for use in providing an automated and quantitative analysis of the liver's morphological characteristics in unstained liver biopsies with high repeatability and accuracy.

Read More
HistoIndex qFIBS 2 1k 10 Nov 2019

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepati...

Date: 10 Nov 2019

qFIBS, a novel automated algorithm developed by HistoIndex, has been shown to accurately distinguish different grades and stages of histological NASH features with a continuous measurement approach. This was highlighted in an international, multicenter collaborative study conducted by pathologists and hepatologists from China, Singapore, Europe and United States.

“In clinical trials today, we depend on the ability to measure critical NASH liver biopsy characteristics especially in determining the extent of fibrosis and steatosis at the various regions of the biopsy, which is very important in assessing post-treatment responses. To assist pathologists in their assessments, it is imperative for pharmaceutical and biotech companies to consider working with a fully quantifiable tool such as qFIBS to provide accurate, standardized and consistent data in clinical trials.” - Dr Stephen Harrison, Medical Director of Pinnacle Clinical Research and President of Summit Clinical Research, and co-author of the multicenter study.

Read More
HistoIndex NASH Preclinical 26 Oct 2019

HistoIndex Announces Global Partnerships to Expand AI-Based...

Date: 26 Oct 2019

The Singapore-based company has fostered partnerships with pharmaceutical and biotech companies, Contract Research Organizations (CROs), academia and government-linked research institutes in empowering NASH drug discovery.

"We are very excited to extend our AI-based SHG platform to preclinical studies to help companies with drug discovery programs select promising lead candidates for further optimization and subsequent clinical development. Our SHG image analysis platform has already been used to analyze the efficacy of a series of promising drug candidates for NASH within various animal models commonly-used by the industry, and we believe these preclinical partnerships will help drive the adoption of our platform significantly." - Dr Poon Thong Yuen, Chief Executive Officer of HistoIndex. 

Read More
LITMUS Prof Quentin Anstee in lab grid 20 Aug 2019

[By Newcastle University] LITMUS – Progress towards diagno...

Date: 20 Aug 2019

Picture Credits: Newcastle University

HistoIndex Joins LITMUS Consortium of Partners to Develop, Validate and Qualify Better Biomarkers for NAFLD Testing.

- A pioneering European research project, designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients.
- Incorporating several new partners also enables access to even more state-of-the art technologies.
- HistoIndex Joins LITMUS Consortium of Partners to Develop, Validate and Qualify Better Biomarkers for NAFLD Testing.

Read More
HI ILBS Media 7 Aug 19 07 Aug 2019

HistoIndex and ILBS Launch Centre of Excellence in New Delhi...

Date: 07 Aug 2019

Picture Credits: Enterprise Singapore

In a cross-border collaboration, HistoIndex and the Institute of Liver & Biliary Sciences (ILBS) in New Delhi, India have jointly launched a Centre of Excellence (CoE) to aid diagnostics and clinical trials focusing on NASH. The CoE is HistoIndex's first Genesis Imaging Service (GIS) partner in India and joins the company's global network of medical, academic and referral laboratory partners who are involved in comprehensive clinical and scientific studies on NASH and other chronic liver conditions. 

Read More
MadrigalWeek 36 Fibrosis SHG2 23 Dec 2018

HistoIndex's Second Harmonic Generation (SHG) Technology: A...

Date: 23 Dec 2018

HistoIndex's AI-based SHG technology has the potential to yield important results from NASH clinical trials.  HistoIndex's SHG technology was featured in Madrigal Pharmaceuticals' Presidential Plenary presentation during AASLD's The Liver Meeting® 2018, for its presentation entitled, "In a Placebo Controlled 36 Week Phase 2 Trial, Treatment with MGL-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in NASH on Serial Liver Biopsy". 

Read More
Dr Poon Thong Yuen LSWM 06 Jul 2018

HistoIndex Welcomes its New CEO on Board!

Date: 06 Jul 2018

HistoIndex has appointed Dr Poon Thong Yuen as its new Chief Executive Officer (CEO) with effect from 1 July 2018. Dr Poon takes over from Dr Gideon Ho, who will continue to drive the global business growth of the company as the Chief Commercial Officer (CCO). 

Says Dr Poon, “Providing clinical trial services to the biopharma industry is the first step for us to work closely with pharmaceutical companies that are developing drugs for NASH. Our eventual goal is to be a Companion Diagnostics platform for NASH.”

Read More
The Progression of NAFLD HistoIndex 08 Jun 2018

A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (N...

Date: 08 Jun 2018

As part of the international NASH Education Program™, HistoIndex has joined over 150 world experts in a global call of action to promote the awareness of NASH in Singapore.

Read More
Thumbnail partnership 1 18 May 2018

HistoIndex and CymaBay Therapeutics Team Up to Advance NASH...

Date: 18 May 2018

Histoindex Pte. Ltd., with the world’s first stain-free Genesis®200 multiphoton digital pathology system, is collaborating with CymaBay Therapeutics, Inc. to evaluate the efficacy of seladelpar in a randomized, double-blind, placebo-controlled, multi-center Phase 2b study of 175 subjects with biopsy-confirmed Nonalcoholic Steatohepatitis (NASH).

Read More
HistoIndex Stain free Liver Tissue Image 11 Jan 2018

Histoindex's Stain-Free Digital Pathology System Receives HS...

Date: 11 Jan 2018

The stain-free Laennec® digital pathology imaging system by HistoIndex® has achieved its first regulated in vitro diagnostics (IVD) product status with the issuance of a Health Sciences Authority (HSA) Class A licence. This is a world’s first achievement for a stain-free digital pathology innovation to be approved for use in a clinical diagnosis setting. 

Read More

1 2 3